HORIBA launches new compact hematology analyzers with combined ESR and CBC/DIFF

Yumizen H550 range expands to introduce new applications and configurable hematology options for small to mid-throughput laboratories

24 Jun 2024
HORIBA Yumizen H550 range

HORIBA’s new Yumizen H550 compact hematology analyzer range now offers combined testing for CBC/DIFF with ESR results from whole blood in 60 seconds.

HORIBA, a global leader in analytical and measurement technology, has expanded its compact hematology instrument range with the launch of new models with erythrocyte sedimentation rate (ESR) on board. The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) now offer combined testing for CBC/DIFF with ESR results from whole blood in 60 seconds, adding a comprehensive profile for inflammatory disease assessment to the instruments’ already extensive functionality.

HORIBA has developed the innovative 'CoRA' (Correlated Rouleaux Analysis) technology to integrate ESR into its three new analyzers. Combining complete blood count (CBC) and 5-population white blood cell differential (DIFF) with rapid ESR, calibrated to the Westergren reference method on one compact analyzer, reduces costs per test and turnaround times, and saves laboratory space. This CoRA technology is patented by HORIBA.

Both the Yumizen H550E and H500E models have been further enhanced by offering new connectivity possibilities for data management through HORIBA’s Yumizen P8000 middleware, along with Yumicare. This remote technical support tool enables secure connection to the instrument to monitor workload, reagent consumption, quality control and instrument alarms.

Other key advancements have included i-DoubleDiff technologies to enhance speed of diagnoses:

  • 'I' for Infectious screening: By using artificial intelligence, the analyzer can display score flags for infectious diseases such as malaria and dengue fever, making it a crucial tool in both advanced and resource-limited healthcare settings.
  • 'DoubleDiff': Normal leucocyte count (lymphocyte, monocyte, neutrophil, eosinophil, and basophil) plus abnormal leucocyte count (IMG, IMM, IML, LIC, ALY). Requiring just two reagents, this increased analytical capability from 27 to 37 parameters, provides deeper insights and more comprehensive results with oncology capabilities.

The Yumizen H550 range offers extensive applications in a variety of clinical laboratory environments and clinical settings, including: critical care, oncology care, infectious disease care, blood banks, satellite laboratories and health centers.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>